Longview Acquisition Corp. II (NYSE:LGV) & Sight Sciences (NASDAQ:SGHT) Critical Comparison
Longview Acquisition Corp. II (NYSE:LGV) & Sight Sciences (NASDAQ:SGHT) Critical Comparison
Longview Acquisition Corp. II (NYSE:LGV – Get Rating) and Sight Sciences (NASDAQ:SGHT – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations and valuation.
朗维尤收购公司II(NYSE：LGV-GET Rating)和纳斯达克(Sequoia Science：SGHT-GET Rating)都是小盘医疗公司，但哪一家更好？我们将根据这两家公司的盈利能力、风险、股息、收益、机构所有权、分析师建议和估值的强弱对它们进行比较。
Insider & Institutional Ownership
内部人与机构所有权
62.1% of Longview Acquisition Corp. II shares are held by institutional investors. Comparatively, 65.2% of Sight Sciences shares are held by institutional investors. 26.4% of Longview Acquisition Corp. II shares are held by insiders. Comparatively, 44.3% of Sight Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
62.1%的Longview Acquisition Corp.II股票由机构投资者持有。相比之下，机构投资者持有Sight Sciences 65.2%的股份。Longview Acquisition Corp.II的26.4%股份由内部人士持有。相比之下，视觉科学44.3%的股份由内部人士持有。强大的机构持股表明，捐赠基金、对冲基金和大型基金管理公司相信，一家公司的长期表现将好于大盘。
Analyst Ratings
分析师评级
This is a summary of current recommendations and price targets for Longview Acquisition Corp. II and Sight Sciences, as reported by MarketBeat.com.
据MarketBeat.com报道，这是对Longview Acquisition Corp.II和Sight Sciences的当前建议和目标价的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Longview Acquisition Corp. II | 0 | 0 | 0 | 0 | N/A |
| Sight Sciences | 0 | 2 | 4 | 0 | 2.67 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 朗维尤收购公司II | 0 | 0 | 0 | 0 | 不适用 |
| 视觉科学 | 0 | 2 | 4 | 0 | 2.67 |
Earnings & Valuation
收益与估值
This table compares Longview Acquisition Corp. II and Sight Sciences' top-line revenue, earnings per share and valuation.
该表格比较了Longview Acquisition Corp.II和Sight Sciences的营收、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Longview Acquisition Corp. II | N/A | N/A | $7.40 million | N/A | N/A |
| Sight Sciences | $48.96 million | 11.73 | -$62.96 million | ($1.79) | -6.66 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| 朗维尤收购公司II | 不适用 | 不适用 | 740万美元 | 不适用 | 不适用 |
| 视觉科学 | 4,896万美元 | 11.73 | -6,296万元 | ($1.79) | -6.66 |
Longview Acquisition Corp. II has higher earnings, but lower revenue than Sight Sciences.
Longview Acquisition Corp.II的收益高于Sight Sciences，但营收低于Sight Sciences。
Volatility & Risk
波动性与风险
Longview Acquisition Corp. II has a beta of 0.05, indicating that its stock price is 95% less volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500.
Longview Acquisition Corp.II的贝塔指数为0.05，表明其股价的波动性比标准普尔500指数低95%。相比之下，Sight Sciences的贝塔系数为1.63，这表明其股价的波动性比标准普尔500指数高出63%。
Profitability
盈利能力
This table compares Longview Acquisition Corp. II and Sight Sciences' net margins, return on equity and return on assets.
此表比较了Longview Acquisition Corp.II和Sight Sciences的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Longview Acquisition Corp. II | N/A | -65.52% | 3.65% |
| Sight Sciences | -130.24% | -42.18% | -33.95% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 朗维尤收购公司II | 不适用 | -65.52% | 3.65% |
| 视觉科学 | -130.24% | -42.18% | -33.95% |
Summary
摘要
Sight Sciences beats Longview Acquisition Corp. II on 7 of the 10 factors compared between the two stocks.
在比较两只股票的10个因素中，有7个超过了Longview Acquisition Corp.II。
About Longview Acquisition Corp. II
关于Longview收购公司II
(Get Rating)
(获取评级)
Longview Acquisition Corp. II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on businesses in the healthcare, industrials, consumer, media, technology, and technology services sector. The company was incorporated in 2020 and is based in New York, New York.
Longview Acquisition Corp.II没有重大业务。拟与一家或多家企业进行合并、资本换股、资产收购、股票购买、重组或类似的业务合并。该公司打算专注于医疗保健、工业、消费者、媒体、技术和技术服务部门的业务。该公司成立于2020年，总部设在纽约。
About Sight Sciences
关于视觉科学
(Get Rating)
(获取评级)
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
视力科学公司是一家眼科医疗设备公司，致力于治疗眼科疾病的外科和非外科技术的开发和商业化。该公司的产品包括眼科医生用来降低成人青光眼患者眼压的治疗设备Omni Surgical System，以及眼科医生和验光师用于治疗干眼病(DED)的可穿戴眼皮技术TearCare System。它通过销售代表和分销商向美国的医院、医疗中心和眼科护理专业人员提供产品。该公司成立于2010年，总部设在加利福尼亚州门洛帕克。
Receive News & Ratings for Longview Acquisition Corp. II Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longview Acquisition Corp. II and related companies with MarketBeat.com's FREE daily email newsletter.
接受Longview收购公司的新闻和评级II Daily-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Longview Acquisition Corp.II和相关公司的最新新闻和分析师评级的每日简要摘要。